Cocrystal Pharma Inc (COCP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.130.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Reduce losses and improve earnings: EPS not reported.
Cocrystal Pharma is advancing clinical trials for antiviral drugs. The new CEO appointment is a positive leadership change. The company showed an earnings beat in late 2025. These factors support potential future value.
The company is loss-making with negative EPS expected through 2027. Recent stock price dropped 35% from highs. No revenue is currently forecasted. The biotech sector is risky and results are uncertain.
The stock trades about 42% below our fair value near $1.73. The market prices in continued losses and no revenue growth. Our view is cautious given the lack of revenue and ongoing losses.
Breaks if: capital runs out or highly dilutive financing needed
Breaks if: clinical development stalls or key trial failures occur
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, given its focus on advancing clinical development in the healthcare sector. The current thesis state is cautious due to recent weak performance and high operating losses.
The market appears to have low expectations for COCP, as indicated by its alignment with peers despite its loss-making status. There is a low fragility tier, suggesting that the stock is not overly sensitive to immediate market shocks.
Management is focused on advancing clinical trials for antiviral candidates, but recent financial results show increasing operating losses. The near-term risk of missing earnings estimates is significant, given the company's smaller size and the high miss rate in its industry.
The long-term thesis hinges on several factors, including the performance of sector bellwethers and the company's ability to manage operating losses effectively. Additionally, guidance cuts or worsening economic indicators could negatively impact sentiment.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on progressing the lead norovirus program CDI-988 through Phase 1b clinical trial with topline data expected by end of 2026.
Stated as a priority in 3 of last 3 quarters. Management expects topline data from the Phase 1b norovirus trial by end of 2026-Q4. Revenue declined from $225,000 in 2026-Q1 to $105,000 in 2026-Q2, reflecting early clinical-stage status. The trajectory shows persistent focus on clinical advancement with limited current revenue impact.
“CEO: 'We expect to report topline data from our Phase 1b norovirus trial by the end of the fourth quarter of 2026.'”
“CEO: 'We expect to report topline data from our Phase 1b norovirus trial by the end of the fourth quarter of 2026.'”
“Company: 'Advancing clinical development of CDI-988 for norovirus and broader antiviral pipeline.'”
Breaks if: EPS loss worsens or remains flat beyond FY27
Over the next 1 to 3 years, COCP faces challenges but has potential if management can execute on its clinical development goals. Not investment advice.